Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 3, 2005, Pages 884-888

  Chambers, Henry F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; CEPHALOSPORIN DERIVATIVE; PENICILLIN BINDING PROTEIN 2A; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA VALVE DISEASE; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; MASS SPECTROMETRY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RABBIT; SPLEEN; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS;

ANIMALS; AORTIC VALVE; CEPHALOSPORINS; DISEASE MODELS, ANIMAL; ENDOCARDITIS, BACTERIAL; HEART VALVE DISEASES; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 14744278669     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.3.884-888.2005     Document Type: Article

References (21)

1. Azoulay-Dupuis, E., J. P. Bedos, J. Mohler, A. Schmitt-Hoffmann, M. Schleimer, and S. Shapiro. 2004. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrob. Agents Chemother. 48:1105-1111.
2. Boyle-Vavra, S., S. K. Berke, J. C. Lee, and R. S. Daum. 2000. Reversion of glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob. Agents Chemother. 44:272-277.
3. Bozdogan, B., D. Esel, C. Whitener, F. A. Browne, and P. C. Appelbaum. 2003. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. 52:864-868. (First published 16 October 2003; http://jac.oupjournals.org/cgi/ content/full/52/5/864.)
4. Chambers, H. F. 1995. In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP 2a. Antimicrob. Agents Chemother. 39:462-466.
5. Chambers, H. F., M. Kartalija, and M. Sande. 1995. Ampicillin, sulbactam, and rifampin combination treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits. J. Infect. Dis. 171:897-902.
6. Chambers, H. F., M. Sachdeva, and S. Kennedy. 1990, Binding affinity of penicillin binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 162:705-710.
7. Climo, M. W., R. L. Patron, and G. L. Archer. 1999. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob. Agents Chemother. 43:1747-1753.
8. Entenza, J. M., P. Hohl, I. Heinze-Krauss, M. P. Glauser, and P. Moreillon. 2002. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. 46:171-177.
9. Fung-Tomc, J. C., J. Clark, B. Minassian, M. Pucci, Y. H. Tsai, E. Gradelski, L. Lamb, I. Medina, E. Huczko, B. Kolek, S. Chaniewski, C. Ferraro, T. Washo, and D. P. Bonner. 2002. In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against methicillin-resistant and -susceptible staphylococci. Antimicrob. Agents Chemother. 46:971-976.
10. Hebeisen, P., I. Heinze-Krauss, P. Angehrn, P. Hohl, M. G. Page, and R. L. Then. 2001. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45:825-836.
11. Heller, S., E. Marrer, M. G. P. Page, S. Shapiro, and L. Thenoz. 2004. Development of endogenous resistance by staphylococci to BAL9141 and comparators. Clin. Microbiol. Infect. 10(Suppl. 3):163.
12. Huang, V., W. J. Brown, and M. J. Rybak. 2004. In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci. Antimicrob. Agents Chemother. 48:2719-2723.
13. Johnson, A. P., M. Warner, M. Carter, and D. M. Livermore. 2002. In vitro activity of cephalosporin RWJ-54428 (MC-02479) against multidrug-resistant gram-positive cocci. Antimicrob. Agents Chemother. 46:321-326.
14. Katayama, Y., H. Z. Zhang, and H. F. Chambers. 2004. PBP 2a mutations producing very-high-level resistance to beta-lactams. Antimicrob. Agents Chemother. 48:453-459.
15. Lim, D., and N. C. Strynadka. 2002. Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus. Nat. Struct. Biol. 9:870-876.
16. Ohtake, N., H. Imamura, H. Jona, H. Kiyonaga, A. Shimizu, M. Moriya, H. Sato, M. Nakano, R. Ushijima, and S. Nakagawa. 1998. Novel dithiocarbamate carbapenems with anti-MRSA activity. Bioorg. Med. Chem. 6:1089-1101.
17. Schmitt-Hoffmann, A., L. Nyman, B. Roos, M. Schleimer, J. Sauer, N. Nashed, T. Brown, A. Man, and E. Weidekamm. 2004. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. 48:2576-2580.
18. Schmitt-Hoffmann, A., B. Roos, M. Schleimer, J. Sauer, A. Man, N. Nashed, T. Brown, A. Perez, E. Weidekamm, and P. Kovacs. 2004. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. 48:2570-2575.
19. Schmitt-Hoffmann, A. H., M. Harsch, M. Heep, M. Schleimer, T. Brown, A. Man, and W. O'Riordan. 2004. BAL5788 in patients with complicated skin and skin structure infections caused by Gram-positive pathogens including methicillin-resistant Staphylococcus species. Interim pharmacokinetic results from 20 patients. Clin. Microbiol. Infect. 10(Suppl. 3):277.
20. Sumita, Y., H. Nouda, K. Kanazawa, and M. Fukasawa. 1995. Antimicrobial activity of SM-17466, a novel carbapenem antibiotic with potent activity against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 39:910-916.
21. Tenover, F. C., M. V. Lancaster, B. C. Hill, C. D. Steward, S. A. Stocker, G. A. Hancock, C. M. O'Hara, S. K. McAllister, N. C. Clark, and K. Hiramatsu. 1998. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J. Clin. Microbiol. 36:1020-1027.